Mark Yates
- Rheumatology top 5%
- Rheumatoid Arthritis Research and Therapies 16
- Systemic Lupus Erythematosus Research 5
- Spondyloarthritis Studies and Treatments 3
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies 6
- Hematology top 10%
- Autoimmune and Inflammatory Disorders Research 3
- Neurology top 10%
-
- COVID-19 and healthcare impacts 6
-
- Lymphoma Diagnosis and Treatment 4
-
- Biosimilars and Bioanalytical Methods 3
Mark Yates
35 papers receiving 784 citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Rheumatology 256
- Infectious Diseases 248
- Hematology 124
- Neurology 125
- Genetics 70
Countries citing papers authored by Mark Yates
This map shows the geographic impact of Mark Yates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Yates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Yates more than expected).
Fields of papers citing papers by Mark Yates
This network shows the impact of papers produced by Mark Yates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Yates. The network helps show where Mark Yates may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Yates, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 2 | |
| 3 | 2023 | 4 | |
| 4 | Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM studybreakdown → | 2023 | 86 |
| 5 | 2022 | 15 | |
| 6 | 2021 | 5 | |
| 7 | 2021 | 35 | |
| 8 | 2021 | 1 | |
| 9 | 2021 | 10 | |
| 10 | 2021 | 13 | |
| 11 | 2021 | 2 | |
| 12 | 2020 | 16 | |
| 13 | 2020 | 127 | |
| 14 | 2020 | 8 | |
| 15 | 2020 | 5 | |
| 16 | 2019 | 37 | |
| 17 | 2019 | 72 | |
| 18 | 2019 | 2 | |
| 19 | 2013 | 1 | |
| 20 | 1999 | 3 |
About Mark Yates
Mark Yates is a scholar working on Rheumatology, Infectious Diseases, Oncology, Rehabilitation and Toxicology, having authored 38 papers that have together received 819 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (16 papers), COVID-19 Clinical Research Studies (6 papers), COVID-19 and healthcare impacts (6 papers), Systemic Lupus Erythematosus Research (5 papers), Lymphoma Diagnosis and Treatment (4 papers), Spondyloarthritis Studies and Treatments (3 papers), Autoimmune and Inflammatory Disorders Research (3 papers) and Biosimilars and Bioanalytical Methods (3 papers). The work is most often cited by research in Rheumatology (256 citations), Infectious Diseases (248 citations), Hematology (124 citations), Neurology (125 citations) and Genetics (70 citations). Mark Yates has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include James Galloway, Katie Bechman, Sam Norton, Maryam Adas, Benjamin D Clarke, Andrew P. Cope, Mark Russell, Sanketh Rampes, Richard D. Barker and Randolph M. Spargo. Their work appears in journals such as Lara D. Veeken, The Journal of Rheumatology, Arthritis & Rheumatology, Journal of Infection and RMD Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.